Cited by 88Statistical Methods in Clinical TrialsBiosimilars and Bioanalytical MethodsPharmaceutical studies and practices

Therapeutic equivalence: fallacies and falsification

Garrett, Andrew D.·2003·Statistics in Medicine

Abstract

The number of studies designed specifically to demonstrate therapeutic equivalence or alternatively non‐inferiority of pharmaceutical treatments has increased dramatically in recent years, during which time awareness of the methodological issues has increased. Regulatory authorities have been quick to recognize the need for specific support and have either published or initiated the creation of relevant guidance. Common misconceptions prevail however regarding sample size estimation and the choice of the most appropriate patient population to analyse while other areas such as equivalence margin specification and covariate adjustment have been neglected. This paper challenges some of the regulatory advice and the interpretation that others have made of this guidance with the aim of stimulating further debate. Copyright © 2003 John Wiley & Sons, Ltd.

Integrity signals

Registry

Crossref · 10.1002/sim.1360

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Regulatory issues frequently also have to be considered in determining the equivalence margin.

    “Frequently, regulatory issues also have to be considered 5 .”

    From Understanding Equivalence and Noninferiority Testing (2011) · cites this paper as [5]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Garrett, A. D.
Affiliations
IQVIA (United Kingdom) (GB)
Corresponding author
Garrett, Andrew D.
Venue
Statistics in Medicine
Publisher
Wiley
Published
2003-02-05
Volume
22
Issue
5
Pages
741-762
ISSN
  • 0277-6715 (ISSN-L)
  • 1097-0258
OpenAlex
W2172036897
Cited by
88
References
1
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 3 · 2021: 6 · 2020: 2 · 2019: 3 · 2018: 4 · 2016: 4 · 2015: 3 · 2014: 8 · 2013: 4 · 2012: 4
FWCI
3.75
Type
journal article
Language
en
Open access
closed
Locations
  • Statistics in Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
therapeutic equivalence, sample size determination, equivalence margin, covariate adjustment, regulatory guidelines, methodological issues, generic drug comparison
MeSH terms
Drug Evaluation, Humans, Research Design, Therapeutic Equivalency, Models, Statistical, Odds Ratio, Randomized Controlled Trials as Topic, Sample Size

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review